Burkholderia pseudomallei
28450
B. pseudomallei is an "accidental pathogen". It is an environmental organism that has no requirement to pass through an animal host in order to replicate. From the point of view of the bacterium, human infection is an evolutionary "dead end". B. pseudomallei is able to invade cells, polymerise actin and to spread from cell to cell, causing cell fusion and the formation of multinucleate giant cells (Wiki: B. pseudomallei).
Melioidosis
B. pseudomallei infects humans and animals and causes the disease melioidosis. It is also capable of infecting plants (Wiki: B. pseudomallei).
The bacterium Burkholderia pseudomallei is a gram-negative saprophytic bacillus that is found predominantly in Southeast Asia and tropical Australia and is the causative agent of the emerging infection melioidosis. Infection of humans with B. pseudomallei may occur by various routes, including via wounds and existing skin lesions, aspiration of contaminated water during near-drowning, and inhalation of organisms. The clinical manifestations of melioidosis are not uniform, and patients can present with pneumonia, skin abscesses, soft tissue abscesses, or osteomyelitis/septic arthritis. Pneumonic melioidosis is presented in over 50% of acute cases of the disease, and disseminated pneumonia is associated with high mortality. Chronic melioidosis usually occurs following acute melioidosis, and relapsing melioidosis can result from the reactivation of a latent B. pseudomallei infection, often due to the withdrawal of antibiotics or the failure to complete prescribed courses of antibiotics (Harland et al., 2007).
Baboon
Papio cynocephalus
9556
Bank vole
Clethrionomys glareolus
447135
Bear
Ursus americanus
9643
Birds
Passeroidea
175121
Brown Trout
Salmo trutta
8032
Buffalo
Bison bison
9901
Carnivores
Vulpes
9625
Cat
Felis catus
9685
Catfishes
Siluriformes
7995
Cattle
Bos taurus
9913
Chicken
Gallus gallus
9031
Chimpanzee
Pan troglodytes
9598
chinchillas
Chinchillidae
10150
Copper Pheasant
Syrmaticus soemmerringii
9067
Deer
Cervus elaphus
9860
Deer mouse
Peromyscus maniculatus
10042
Dog
Canis familiaris
9615
Ducks
Anas
8835
Ferret
Mustela putorius furo
9669
Fish
Hyperotreti
117565
Gerbil
Gerbillina
10045
Goat
Capra hircus
9925
Gray wolf
Canis lupus
9612
Guinea pig
Cavia porcellus
10141
Hamster
Mesocricetus auratus
10036
Horse
Equus caballus
9796
Human
Homo sapiens
9606
Macaque
Macaca fascicularis
9541
Mongolian Gerbil
Meriones unguiculatus
10047
Monkey
Platyrrhini
9479
Mouse
Mus musculus
10090
None
None
Parrot
Psittacidae
9224
Pig
Sus scrofa
9823
Rabbit
Oryctolagus cuniculus
9986
Rainbow trout
Oncorhynchus mykiss
8022
Rat
Rattus
10114
Raven
Corvus corax
56781
sei whale
Balaenoptera borealis
9768
Sheep
Ovis aries
9940
Squirrel
Spermophilus richardsonii
37591
Tree shrew
Tupaiidae
9393
Trouts, salmons & chars
Salmoninae
504568
Turkey
Meleagris gallopavo
9103
Vole
Microtus ochrogaster
79684
Water buffalo
Bubalus bubalis
391902
B. pseudomallei DNA vaccine encoding Flagellin Protein
VO_0011538
DNA vaccine
Research
pcDNA3 [Ref1361:Chen et al., 2006]
Intramuscular injection (i.m.)
Intramuscular injection (i.m.)
DNA vaccine construction
Balb/c
Six-week-old female Balb/c mice from groups 1–3 were injected intramuscularly (i.m.) with pcDNA3/fliC in PBS (50, 100 or 150 μg); whereas those from group 4 (the negative control) were injected (i.m) with vector DNA(150 μg; pcDNA3) in PBS, whilst those from group 5 (the positive control) were injected subcutaneously with recombinant flagellin antigens (50 μg) emulsified in complete Freund's adjuvant. Each animal from group 5 was subsequently boosted with the same dose of flagellin in incomplete Freund's adjuvant 14 days subsequent to the initial flagellin injection. The animals in groups 1–4 were boosted twice with an identical dose of plasmid DNA, once at 7 days and then again at 14 days after the initial injection (Chen et al., 2006).
Subsequent intravenous challenge of the vaccinated Balb/c mice with 10(5)CFU of B. pseudomallei resulted in the number of bacterial cells detected in liver and/or spleen being significantly reduced in the flagellin plasmid DNA vaccinated mice. At 7 days subsequent to infection of B. pseudomallei, 5/6 (83%) of flagellin plasmid DNA vaccinated mice had survived (Chen et al., 2006).
The immunized mice were infected via the tail vein with 105 CFU of mixed B. pseudomallei suspended in sterile PBS (50 μl). As control groups, the mice received either sterile PBS or vector DNA (Chen et al., 2006).
Mice spleen cells were collected after an eight-week immunization. The up-regulation of IFN-γ production among the mice immunized with pcDNA3/fliC was significantly greater than among the mice either immunized with recombinant flagellin or vaccinated with vector DNA only (Chen et al., 2006).
B. pseudomallei Subunit LolC Protein Vaccine
VO_0011436
Subunit vaccine
Research
Intraperitoneal injection (i.p.)
Intraperitoneal injection (i.p.)
Recombinant protein preparation
BALB/c
Female 5- to 6-week-old BALB/c mice were immunized with the purified recombinant LolC protein given with adjuvant (Harland et al., 2007).
The recombinant LolC protein afforded significant protection against the B. pseudomallei challenge (Harland et al., 2007).
Mice immunized with the LolC protein or appropriate controls were challenged with B. pseudomallei K96243 on day 70 (Harland et al., 2007).
B. pseudomallei Subunit PotF Protein Vaccine
VO_0011438
Subunit vaccine
Research
Intraperitoneal injection (i.p.)
Intraperitoneal injection (i.p.)
Recombinant protein preparation
BALB/c
Female 5- to 6-week-old BALB/c mice were immunized with the purified recombinant PotF protein given with adjuvant (Harland et al., 2007).
Immunization with the PotF protein domain afforded significant protection against a subsequent challenge with B. pseudomallei (Harland et al., 2007).
Mice immunized with the PotF protein or appropriate controls were challenged with B. pseudomallei K96243 on day 70 (Harland et al., 2007).
Burkholderia pseudomallei aroC deletion mutant vaccine
VO_0002825
Live, attenuated vaccine
Research
Intraperitoneal injection (i.p.)
An unmarked aroC deletion mutant of B. pseudomallei strain A2 was constructed using a sucrose counter-selection strategy. The aroC deletion in the resultant mutant, designated A2DeltaaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compound (Srilunchang et al., 2009).
Intraperitoneal injection (i.p.)
Gene mutation
Compared to the parental wild type strain, A2DeltaaroC was highly attenuated for virulence following intraperitoneal introduction into BALB/c and C57BL/6 mice (Srilunchang et al., 2009).
C57BL/6 mice immunized intraperitoneally with A2DeltaaroC were significantly protected against a challenge dose of 6,000 cfu (20 x LD50) (Srilunchang et al., 2009).
Burkholderia pseudomallei asd mutant vaccine
VO_0002826
Live, attenuated vaccine
Research
intranasal immunization
intranasal immunization
Gene mutation
This asd mutant is from Burkholderia pseudomallei (Norris et al., 2011).
An asd mutant is highly attenuated in mice (Norris et al., 2011).
An asd mutant induces protection against challenge with wild type B. pseudomallei (Norris et al., 2011).
Burkholderia pseudomallei purM mutant vaccine
VO_0002827
Live, attenuated vaccine
Research
Intraperitoneal injection (i.p.)
Intraperitoneal injection (i.p.)
Gene mutation
This purM mutant is from Burkholderia pseudomallei (Breitbach et al., 2008).
A purM mutant is attenuated in mice (Breitbach et al., 2008).
A purM mutant induced protection from challenge with wild type B. pseudomallei (Breitbach et al., 2008).
Burkholderia pseudomallei purN mutant vaccine
VO_0002828
Live, attenuated vaccine
Research
Intraperitoneal injection (i.p.)
Intraperitoneal injection (i.p.)
Gene mutation
This purN mutant is from Burkholderia pseudomallei (Breitbach et al., 2008).
A purN mutant was attenuated in mice, as mice did not show any clinical symptoms of illness (Breitbach et al., 2008).
A purN induced strong protection in mice from challenge with wild type B. pseudomallei (Breitbach et al., 2008).
aroC
Burkholderia pseudomallei 1106a
4899749
126453136
BURPS1106A_1713
CP000572
YP_001065984
357348
I
1672513
1673622
+
chorismate synthase
6.35
36184.83
369
catalyzes the formation of chorismate from 5-O-(1-carboxyvinyl)-3-phosphoshikimate in aromatic amino acid biosynthesis
>gi|126451443:1672513-1673622 Burkholderia pseudomallei 1106a chromosome I, complete genome
TATGTCCGGCAACACCCTCGGCACGCTTTTCACTGTCACGACCTTCGGCGAATCGCACGGCCCCGCGATC
GGCTGCGTGATCGACGGCTGCCCGCCGGGCATGGCGCTCACGGAAGCCGACGTCCAGCTCGAGCTCGACC
GCCGCAAGCCCGGCACGTCGCGCCACGTCACGCAGCGTCAGGAGCCCGACCAGGTCGAGATCCTGTCCGG
CGTGTTCGAGGGCGTGACGACCGGCGCGCCGATCGCGCTCCTGATCCGCAACACCGACCAGCGCAGCAAG
GACTACGGCAACATCGCCGAGACGTTCCGCCCGGGCCATGCCGATTACACCTACTGGCAAAAGTACGGCG
TGCGCGACTATCGCGGCGGCGGCCGCTCGTCCGCGCGGCTGACGGCGCCCGTCGTCGGCGCCGGCGCGAT
CGCGAAGAAGTGGCTGCGCGAGCGCTTCGGCGTCGAGGTGCGCGGCTACATGAGCGCGCTCGGCGAAATC
GAGATCCCGTTCGTCGACTGGTCGCACGTGCGCGAGAACCCGTTCTTCGCGCCGAACGCCGACATCGTGC
CGCAACTCGAGGGCTACATGGACGCGCTGCGCAAGGACGGCGATTCGATCGGCGCGCGCATCGATGTCGT
CGCGTCGGGCGTGCCGGTCGGCTGGGGCGAGCCGCTGTTCGACCGGCTCGACGCCGACATCGCGCACGCG
ATGATGGGGATCAACGCGGTGAAGGGCGTCGAGATCGGCGCGGGTTTCGCGAGCGTCGCGCAGCGCGGTT
CGGTGCACGGCGACGAGCTGACGCCGGACGGCTTCGTCGGCAATCACGCGGGCGGCGTGCTCGGCGGCAT
CTCGACGGGGCAGGACATCACGGTGTCGATCGCGATCAAGCCGACGTCGAGCATTCGCACGCCGCGCCGC
TCGATCACGCGGGCGGGCGAACCCGCCGTCGTCGAGACGTTCGGCCGCCACGACCCGTGCGTCGGGATTC
GCGCGACGCCGATCGCCGAATCGATGCTCGCGCTCGTGCTGATCGATCACGCGCTGCGGCACCGCGCGCA
GTGCGGCGACGTGTCGAGCGCGACGCCGAGGATCGCCGCGCGCGCGCCGGACGCGCAATG
>gi|126453136|ref|YP_001065984.1| chorismate synthase [Burkholderia pseudomallei 1106a]
MSGNTLGTLFTVTTFGESHGPAIGCVIDGCPPGMALTEADVQLELDRRKPGTSRHVTQRQEPDQVEILSG
VFEGVTTGAPIALLIRNTDQRSKDYGNIAETFRPGHADYTYWQKYGVRDYRGGGRSSARLTAPVVGAGAI
AKKWLRERFGVEVRGYMSALGEIEIPFVDWSHVRENPFFAPNADIVPQLEGYMDALRKDGDSIGARIDVV
ASGVPVGWGEPLFDRLDADIAHAMMGINAVKGVEIGAGFASVAQRGSVHGDELTPDGFVGNHAGGVLGGI
STGQDITVSIAIKPTSSIRTPRRSITRAGEPAVVETFGRHDPCVGIRATPIAESMLALVLIDHALRHRAQ
CGDVSSATPRIAARAPDAQ
Virmugen
The aroC deletion in the resultant mutant, designated A2ΔaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compounds. The constructed unmarked aroC mutant of B. pseudomallei is attenuated in both BALB/c and C57Bl/6 mice and is able to confer significant protection in C57Bl/6 mice [Ref1722:Srilunchang et al., 2009].
asd
Burkholderia pseudomallei 1026b
2358232
CDD:200773
CDD:162144
884204
II
2291554
2292675
-
aspartate beta-semialdehyde dehydrogenase
5.09
37414.1
90
Rossmann-fold NAD(P)(+)-binding proteins; cl09931
>gi|126455463:2291554-2292675 Burkholderia pseudomallei 1106a chromosome chromosome II, complete sequence
TTTACTTGTCGAGCAGAATGCGCAGCATCCGGCGCAGCGGCTCGGCCGCGCCCCACAGCAATTGATCGCC
GACGGTAAATGCCGACAGGTATTCGCCACCCATCGCGAGCTTGCGCAGGCGGCCGACCGGCACCGACAGC
GTGCCCGTCACCTTCGCCGGCGACAGATCGCGCATCGACGCCTCGCGCTCGTTCGGCACGACCTTCACCC
AGTCGTTCGCCGATGCGAGCATGCCGTTGATCTCGTCGAGCGGCACGTCCTTCTTCAGCTTGATCGTGAG
CGCCTGCGAGTGGCAGCGCATCGCGCCGATCCGCACGCACAGGCCGTCGACCGGAATCGAGCCCGGCTCG
CCCATCGCCGGCTTGCCGAGGATCTTGTTGGTTTCCGCGCCGCCCTTCCACTCTTCCTTCGACATGCCGT
TGCCGAGATCCTTGTCGATCCACGGAATCAGCGAGCCGGCAAGCGGCACGCCGAACTGGCTCGTCGGCAT
CGCGTCGCCGTTCATCGCGGCGAGCACGCGGCGGTCGATATCGAGGATCGCCGAGGCCGGATCGGCGAGC
TGCGCCGCCACCGCGCCGTTGAGCGCGCCCATCTGCGCGAGCAGCTCGCGCATGTTCTGCGCGCCCGCGC
CCGACGCGGCCTGGTAGGTCATCGCCGTCATCCAGTCGACGAGGTTCTCGCGGAACAGGCCGCCCAGCGC
CATCAGCATCAGGCTGACCGTGCAGTTGCCGCCGATGAAGTTCTTCGTGCCGTTGACGAGCGCGTCCTTG
ATCACGTTCAGGTTCACGGGATCGAGAATGATCACCGCGTCGTCCTTCATCCGCAGCGACGACGCCGCAT
CGATCCAGTAGCCGTTCCAGCCGGCCGCGCGCAGCTTCGGGAACACGTCGCTCGTGTAATCGCCGCCCTG
GCACGTGATGATCGCGTCGCACTTCTTCAGGTCGTCGATGCTCGTCGCATCCTTGAGCGTGGTCTCGTTT
TTCGCGAACGACGGCGCCTTGCCGCCCGCGTTGCTGGTGCTGAAAAACACCGGCTCGATCAGATCGAAAT
CGCCTTCTTCCTGCATGCGCTGCATCAGCACGCTGCCGACCATGCCGCGCCAACCTACGAGACCTACGTT
CA
>gi|2358232|gb|AAB69093.1| aspartate beta-semialdehyde dehydrogenase [Burkholderia pseudomallei 1026b]
CQGGDNASDVFPKPRAAGWNGYWIDAASSLRMKDDAVIILDPVNLNVIKDALVNGTKNFIGGNCTVSLML
MALDGLFRENLVDWMTAMTY
Virmugen
An asd mutant is highly attenuated in mice. This mutant was also able to protect against acute inhalation melioidosis caused by challenge with wild type B. pseudomallei [Ref2078:Norris et al., 2011].
fliC
VO_0011303
1929918
CDD:236344
884204
?
flagellin
4.84
37016.41
451
flagellin; Reviewed
>AAB51476.1 flagellin [Burkholderia pseudomallei 1026b]
MLGINSNINSLVAQQNLNGSQGALSQAITRLSSGKRINSAADDAAGLAIATRMQTQINGLNQGVSNANDG
VSILQTASSGLTSLTNSLQRIRQLAVQASNGPLSASDASALQQEVAQQISEVNRIASQTNYNGKNILDGS
AGTLSFQVGANVGQTVSVDLTQSMSAAKIGGGMVQTGQTLGTIKVAIDSSGAAWSSGSTGQETTQINVVS
DGKGGFTFTDQNNQALSSTAVTAVFGSSTAGTGTAASPSFQTLALSTSATSALSATDQANATAMVAQINA
VNKPQTVSNLDISTQTGAYQAMVSIDNALATVNNLQATLGAAQNRFTAIATTQQAGSNNLAQAQSQIQSA
DFAQETANLSRAQVLQQAGISVLAQANSLPQQVLKLLQ
Protective antigen
Flagellin encoding plasmid DNA was injected into Balb/c mice intramuscularly and this elicited both a humoral and a cellular immune response. Subsequent intravenous challenge of the vaccinated Balb/c mice with 10^5CFU of B. pseudomallei resulted in the number of bacterial cells detected in liver and/or spleen being significantly reduced in the flagellin plasmid DNA vaccinated mice. At 7 days subsequent to infection of B. pseudomallei, 5/6 (83%) of flagellin plasmid DNA vaccinated mice had survived [Ref1361:Chen et al., 2006].
Ifng (Interferon gamma)
Mouse
15978
33468859
NM_008337
NP_032363.1
MGI:107656; UniProt:P01580
10090
?
>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC
>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC
IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
Vaximmutor
The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes [Ref2101:Wang et al., 2009].
LolC/E
Burkholderia pseudomallei K96243
VO_0010921
3093214
53719887
BPSL2277
CP009538
YP_108873
272560
1
2742869
2744122
-
lipoprotein releasing system transmembrane protein
9.43
41147.07
417
Similar to Escherichia coli lipoprotein releasing system transmembrane protein LolE SWALL:LOLE_ECOLI (SWALL:P75958) (413 aa) fasta scores: E(): 1.3e-42, 34.54% id in 414 aa, and to Ralstonia solanacearum probable lipoprotein releasing system transmembrane rsc1117 or rs05757 SWALL:Q8Y0C7 (EMBL:AL646062) (416 aa) fasta scores: E(): 1.4e-112, 71.46% id in 417 aa
>NC_006350.1:2742869-2744122 Burkholderia pseudomallei K96243 chromosome 1, complete sequence
GTCATTCATAGCGCAGCGCCTCCGCCGGGCGCACCTTCGCGCCGCGCCAGCTCGGATAGAGCGTCGCGAG
CGCGGACAGCGCGAAAGCGATCACGCCGATCTTGATCACGTCGCCCGCGACGAGCTCGGACGGCAGCTCG
CTGATGAAGTACACCGACGGCGGCAGGAACTGCACGCCGAACGCATGCTCGATCATCGGAATGAGCCACG
GAATGCTCCACGCGATCAGGCAGCCGAGCGCGACGCCCGTCGCGGTCCCGACGAAGCCGATCGTCACGCC
CTGCACGACGAAGATCTTCATGATCGAGCCCGGCTGCGCGCCGAGCGTGCGCAGGATCGCGATGTCCGCC
TGCTTGTTCGTCACGGTCATCACGAGCGACGACACGAGATTGAACGCCGCGACCGCGATGATCAGCGTGA
GGATGATGAACATCATCCGCTTCTCGATCTGCACCGCGGAGAACCACGTCTTGTTCTGCTGCGTCCAGTC
GCGGATGTACAGGTCGCCCGACAGCGTGTGCGCGAGCTCGCGCGCGACCTGCGGCGCCTTCTGCATGTCC
GTGAGGCGCAGCCGCACGCCCGTCGGCGCGGGCAGCCTGAAGAGCGCCTGCGCATCCTGGATGTCGATCA
TCGCAAGCGTGCTGTCGTATTCGTAGTGCCCGGACTCGAAGATGCCGACCACCGTGAACTGCTTCAGGCG
CGGCATCATCCCGGCCGGCGTGATCGTGCCTTCCGGCGCGACGAGCGTGACCTTGTCGCCGACGCCCACG
CCGAGATTGCCCGCGAGCGCGTTGCCGAGCACGATCCCGAACTGGCCGGGCGCGAGCGCGGTGAGCGCGC
CCGCCTTCATGTCCTTGCCGATGTCGGACACCTGCGGCTCGAGCGACGGCTCGACGCCGCGCAGCATCAC
GCCGCTCACCGCGTCCTGCCGCGTGAGCAGCGCCTGCGCGTCGACATACGGCGCCGCGCCGATCACCGAG
CGGTTCAGGCGCGCTTCCTTCGCGGTCAGTTGCCAGTCGGGCATCGAGCCCGTCGGCGAGAAGATCTCGA
CGTGCGCGAGCACCGACAGCATCCGGTCGCGCACCTCTTTCTGGAAGCCGTTCATCACCGACAGCACGAC
GATGAGCGCCGCGACGCCGAGCGCGATCCCGAGCATCGACACGAGCGCGATGAAGGAAATGAAGCCGTTG
CCGGTCGTGCGTTTGCCGGCGCGCGTGTAGCGCCAGCCGATCTGCCATTCGTACGGGAGTTTCA
>YP_108873.1 lipoprotein releasing system transmembrane protein [Burkholderia pseudomallei K96243]
MKLPYEWQIGWRYTRAGKRTTGNGFISFIALVSMLGIALGVAALIVVLSVMNGFQKEVRDRMLSVLAHVE
IFSPTGSMPDWQLTAKEARLNRSVIGAAPYVDAQALLTRQDAVSGVMLRGVEPSLEPQVSDIGKDMKAGA
LTALAPGQFGIVLGNALAGNLGVGVGDKVTLVAPEGTITPAGMMPRLKQFTVVGIFESGHYEYDSTLAMI
DIQDAQALFRLPAPTGVRLRLTDMQKAPQVARELAHTLSGDLYIRDWTQQNKTWFSAVQIEKRMMFIILT
LIIAVAAFNLVSSLVMTVTNKQADIAILRTLGAQPGSIMKIFVVQGVTIGFVGTATGVALGCLIAWSIPW
LIPMIEHAFGVQFLPPSVYFISELPSELVAGDVIKIGVIAFALSALATLYPSWRGAKVRPAEALRYE
Protective antigen
LolC was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the LolC protein domain afforded significant protection against a subsequent challenge with B. pseudomallei. LolC provided a greater level of protection when it was administered with immune-stimulating complexes complexed with CpG oligodeoxynucleotide 10103. Immunization with LolC also protected against a subsequent challenge with a heterologous strain of B. pseudomallei, demonstrating the potential utility of this protein as a vaccine antigen for melioidosis [Ref1360:Harland et al., 2007].
PotF
Burkholderia pseudomallei K96243
VO_0010922
3095748
53721504
BPSS0467
BX571966
YP_110489
272560
2
636534
637655
-
ABC transporter substrate-binding protein
6.89
37606.43
373
Similar to Escherichia coli putrescine-binding periplasmic protein precursor PotF or b0854 SWALL:POTF_ECOLI (SWALL:P31133) (370 aa) fasta scores: E(): 3.3e-67, 49.3% id in 357 aa, and to Pseudomonas aeruginosa polyamine transport protein pa0301 SWALL:Q9I6J0 (EMBL:AE004468) (365 aa) fasta scores: E(): 6.3e-69, 49.59% id in 367 aa. Possible alternative translational start site
>NC_006351.1:636534-637655 Burkholderia pseudomallei K96243 chromosome 2, complete sequence
ATCAGTGTCCCGTCTTCAATTGCGCCCACAGACGGTTCTCGAGCCGCAGGATGTCGGCGGGCATCGGCCG
CATCAGCGTCATCTTCTTGAGCACGTCCTCGGGCGGGTAGACGGTCGGGTCCTGCGCGACGGCGGGCACG
ACGAACTGTCGCGCCGCGCGGTTCGCGCTCGGGTAGAACACTTCGTTGGTGATCGCCGCGTTGACCTTCG
GGTCCTCGATGTAGTTGATCCACTTCAGCGCGGCTTCCGCGTGCGGCGCATCCTTCGGGATCACCATCAC
GTCGAACCACAGCAGGCCGCCTTCCTTCGGATTCGAGAACTTGATGTCGTACGGGCGCTTCGCCTCGGCC
GAGCGGCGATGCGCGATGCCGACGTCGCCCGACCAGCCGAGCGCGACGCATACGTCGTTGTTCGCGAGAT
CGTTGATGTAGCCGGACGAGTTGAATTGCGTGATGTACGGGCGGACTTTCTTCAGCACCTCGAACGCCGC
CTGGTAATCGGCCGGGTTCGTGCTGTTCGGATTCCTGCCCATGTATTGTAGCGTCGCGGCGAACACGTCG
ACCGCCTGATCGAGGAACGATACGCCGCAGCCCTTGAGCTTGGATACGTTCGCCGGATCGAGCACGAGCG
CCCAGCTGTCGACGGGCGCGTTCTCGCCGAGCGCCTTCTTCACCGCCTGCACGTTGTAGCCGAGGCCGTC
GGTGCCGAACGCCCACGGCACGCCGTACTGGTTGCCCGGATCGGCGTCGGCGATCATCTTCATCAGCGTC
GGATCGAGGTTCGACAGGTTCGGCAGCTTCGATTTGTCGAGCTTCTGGTAGACGCCCGCCTGAATCTGCT
TGGCCATGTAGTTCGACGTCGGCACGACGATGTCGTAGCCGGAGCTGCCCGCGAGCAGCTTCGCCTGCAG
CGTGTCGTCGCTGTCGTAGTTGTCGTACTTGACGTGGATGCCGGATTGCTTCTCGAAGTTCGGGATCGTG
TCCTTCGCGATGTAGTCCGACCAGTTGTACACGTTCAGCTCGGCGCCGGCCGCGTGCGCGGCCGGCAGGG
CGAGCGCCGACGCGCCGGCGAGCGCGACGAGCGCTGCGCGCGCGACCGCATGACGAAGATGGCTCACACT
CA
>YP_110489.1 ABC transporter substrate-binding protein [Burkholderia pseudomallei K96243]
MSVSHLRHAVARAALVALAGASALALPAAHAAGAELNVYNWSDYIAKDTIPNFEKQSGIHVKYDNYDSDD
TLQAKLLAGSSGYDIVVPTSNYMAKQIQAGVYQKLDKSKLPNLSNLDPTLMKMIADADPGNQYGVPWAFG
TDGLGYNVQAVKKALGENAPVDSWALVLDPANVSKLKGCGVSFLDQAVDVFAATLQYMGRNPNSTNPADY
QAAFEVLKKVRPYITQFNSSGYINDLANNDVCVALGWSGDVGIAHRRSAEAKRPYDIKFSNPKEGGLLWF
DVMVIPKDAPHAEAALKWINYIEDPKVNAAITNEVFYPSANRAARQFVVPAVAQDPTVYPPEDVLKKMTL
MRPMPADILRLENRLWAQLKTGH
Protective antigen
PotF was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the PotF protein domain afforded significant protection against a subsequent challenge with B. pseudomallei [Ref1360:Harland et al., 2007].
purM
Burkholderia pseudomallei K96243
3092877
53720427
BPSL2818
BX571965
YP_109413
272560
1
3369942
3370997
-
phosphoribosylaminoimidazole synthetase
4.98
33766.88
351
Also known as purGcatalyzes the formation of 1-(5-phosphoribosyl)-5-aminoimidazole from 2-(formamido)-N1-(5-phosphoribosyl)acetamidine and ATP in purine biosynthesis
>gi|53717639:3369942-3370997 Burkholderia pseudomallei K96243 chromosome chromosome 1, complete sequence
GTCAGACCACGACCGTCTGCGCCTCGCCTTCGCGGCTCGCGCGCACGGTGCCGATCTTCCATACCTGCTC
GCCCGCGTCGGCCAGTTGGCGGAGCGCGTCGTCCGCGTCGGCGGCCGACACGATCACGGCCATCCCGATC
CCGCAGTTGAACACGCGGTGCATCTCCGCATCGGCGACGCCGCCGTGCTGCCGCAGCCACTGGAACAGCG
GCGGCAGCGGCCATGCGTGCTGGTCGAGTTCGGCCGTGAGGCCGTCGCGCAGCACGCGCGGAATGTTCTC
GACGAGGCCGCCGCCCGTGATGTGCGCCATTCCCTTCACCGCGATCTTCTCCATCAGCGCGAGGAGCGGC
TTCACGTAGATGCGCGTCGGCGCCATCAGCGCGTCGGCGAGCGAGCGGCCGTGGAAATCGGCCGACAGGT
CCGGATTCGCGCGCTCGATGATCTTGCGCACGAGCGAGAAACCGTTCGAATGGATGCCGCTCGACGCGAG
GCCCAGCACGACGTCGCCCTCGGCGATCGTGCTGCCGTCAATGATCTTGCTCTTCTCGACCGCGCCGACC
GCGAAGCCCGCCAGATCGTATTCGCCGTCCGGGTACATGCCCGGCATCTCGGCCGTCTCGCCGCCGATCA
GCGCGCAGCCCGCCAGCTCGCAGCCCGTCGCGATGCCCTTGACGACGGTCGCGGCCGTCTCGACGTCGAG
CTTGCCGCACGCGAAGTAGTCGAGGAAGAACAGCGGCTCGGCGCCCTGCACGAGAATGTCGTTTACGCTC
ATCGCGACGAGATCCTGGCCGACCGTATCGTGTTTGTTCAGATGAAACGCGAGCTTGAGCTTCGTGCCGA
CGCCGTCCGTGCCCGATACGAGCACGGGCTCCCGGTACTTCTTCGGCACCTCGAACAGCGCGCCGAACCC
GCCGATGCCGCCGAGCACGCCGTCGCGCAGCGTTTTCTTCGCAAAGGGCTTGATCTTGTCGACGAGCGCG
TCGCCCGCGTCGATGTCGACGCCCGCGTCACGGTAGGACAGGCCCTGGGCGTCGGGAGCGGATTTCGGAG
GATTCA
>gi|53720427|ref|YP_109413.1| phosphoribosylaminoimidazole synthetase [Burkholderia pseudomallei K96243]
MNPPKSAPDAQGLSYRDAGVDIDAGDALVDKIKPFAKKTLRDGVLGGIGGFGALFEVPKKYREPVLVSGT
DGVGTKLKLAFHLNKHDTVGQDLVAMSVNDILVQGAEPLFFLDYFACGKLDVETAATVVKGIATGCELAG
CALIGGETAEMPGMYPDGEYDLAGFAVGAVEKSKIIDGSTIAEGDVVLGLASSGIHSNGFSLVRKIIERA
NPDLSADFHGRSLADALMAPTRIYVKPLLALMEKIAVKGMAHITGGGLVENIPRVLRDGLTAELDQHAWP
LPPLFQWLRQHGGVADAEMHRVFNCGIGMAVIVSAADADDALRQLADAGEQVWKIGTVRASREGEAQTVV
V
Virmugen
Mice that were challenged with a higher dose of mutant 56:65 purM were protected [Ref1796:Breitbach et al., 2008].
purN
Burkholderia pseudomallei K96243
3092878
53718549
BPSL0908
BX571965
YP_107535
272560
1
1060390
1061052
?
phosphoribosylglycinamide formyltransferase
6.08
21138.36
220
glycinamide ribonucleotide transformylase; GAR Tfase; catalyzes the synthesis of 5'-phosphoribosylformylglycinamide from 5'-phosphoribosylglycinamide and 10-formyltetrahydrofolate; PurN requires formyl folate for the reaction unlike PurT which uses formate
>gi|53717639:1060390-1061052 Burkholderia pseudomallei K96243 chromosome chromosome 1, complete sequence
GATGAAAAAACTTGTCATCCTGATTTCCGGCCGCGGCAGCAACATGGAGGCCATCGTACGCGCCTGCGCG
CGCGAAGGCTGGCCCGCCGAGGTCGCCGCCGTGATTTCCAACCGGCCGGGCGCGGCCGGCCTCGAATTCG
CGGCGTCGCACGGCATCGCGACGGCCGTCGTCGACCACCGCGCGTTCGACGGCCGCGACAGCTTCGATGC
GGCGCTCGCCGCCGAAATCGACCGCTTCGCCCCCGATCTCGTCGTGCTCGCCGGCTTCATGCGCATTCTC
ACGCCGGCGTTCGTCGCCAAATATGAGGGGCGGATGCTCAACATCCATCCGTCGCTGCTGCCGAGCTTCA
AGGGCATTCATACGCATCAGCAGGCGCTCGACGCGGGCGTCGCGCTGCACGGCGCATCCGTCCACTTCGT
GATTCCGGAGCTCGACAGCGGCGCGATCGTCGCGCAGGCGGCCGTGCCCGTCGTCGCGGGCGACGATGCC
GATGCGCTCGCCGCGCGCGTGCTCGCCGCCGAGCACACGCTGTATCCGCGCGCGGTGCGCTGGTTCGTCG
AAGGCAAGCTGCGCCTCGACGCGGGGCGCGCCATCGTCGCGCCCGACGAGGCGCGCTGGCTGTTCGCGGA
TGCGATCGACACGTCGACGAGCGAGGGCGTATG
>gi|53718549|ref|YP_107535.1| phosphoribosylglycinamide formyltransferase [Burkholderia pseudomallei K96243]
MKKLVILISGRGSNMEAIVRACAREGWPAEVAAVISNRPGAAGLEFAASHGIATAVVDHRAFDGRDSFDA
ALAAEIDRFAPDLVVLAGFMRILTPAFVAKYEGRMLNIHPSLLPSFKGIHTHQQALDAGVALHGASVHFV
IPELDSGAIVAQAAVPVVAGDDADALAARVLAAEHTLYPRAVRWFVEGKLRLDAGRAIVAPDEARWLFAD
AIDTSTSEGV
Virmugen
Although 30:93a purN -immunized mice were challenged with a 10-fold higher dose of WT E8, mice were strongly protected and showed no signs of clinical illness until the experiment was terminated [Ref1796:Breitbach et al., 2008].
Breitbach et al., 2008
journal
Breitbach K, Köhler J, Steinmetz I
Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle
2008
102 Suppl 1
S89-94
Transactions of the Royal Society of Tropical Medicine and Hygiene
Casey et al., 2016
journal
Casey WT, Spink N, Cia F, Collins C, Romano M, Berisio R, Bancroft GJ, McClean S
Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis
2016
34
23
2616-2621
Vaccine
Chen et al., 2006
journal
Chen YS, Hsiao YS, Lin HH, Yen CM, Chen SC, Chen YL
Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin
2006
24
6
750-758
Vaccine
Druar et al., 2008
journal
Druar C, Yu F, Barnes JL, Okinaka RT, Chantratita N, Beg S, Stratilo CW, Olive AJ, Soltes G, Russell ML, Limmathurotsakul D, Norton RE, Ni SX, Picking WD, Jackson PJ, Stewart DI, Tsvetnitsky V, Picking WL, Cherwonogrodzky JW, Ketheesan N, Peacock SJ, Wiersma EJ
Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents
2008
52
1
78-87
FEMS immunology and medical microbiology
Gourlay et al., 2015
journal
Gourlay LJ, Thomas RJ, Peri C, Conchillo-Solé O, Ferrer-Navarro M, Nithichanon A, Vila J, Daura X, Lertmemongkolchai G, Titball R, Colombo G, Bolognesi M
From crystal structure to in silico epitope discovery in the Burkholderia pseudomallei flagellar hook-associated protein FlgK
2015
282
7
1319-1333
The FEBS journal
Haque et al., 2006
journal
Haque A, Chu K, Easton A, Stevens MP, Galyov EE, Atkins T, Titball R, Bancroft GJ
A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins
2006
194
9
1241-1248
The Journal of infectious diseases
Harland et al., 2007
journal
Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS
Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis
2007
75
8
4173-4180
Infection and immunity
Harland et al., 2007
journal
Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS
Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis
2007
75
8
4173-4180
Infection and immunity
Nelson et al., 2004
journal
Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW
Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
2004
53
Pt 12
1177-1182
Journal of medical microbiology
Norris et al., 2011
journal
Norris MH, Propst KL, Kang Y, Dow SW, Schweizer HP, Hoang TT
The Burkholderia pseudomallei {Delta}asd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice
2011
Infection and immunity
Srilunchang et al., 2009
journal
Srilunchang T, Proungvitaya T, Wongratanacheewin S, Strugnell R, Homchampa P
Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2
2009
40
1
123-130
The Southeast Asian journal of tropical medicine and public health
Tippayawat et al., 2009
journal
Tippayawat P, Saenwongsa W, Mahawantung J, Suwannasaen D, Chetchotisakd P, Limmathurotsakul D, Peacock SJ, Felgner PL, Atkins HS, Titball RW, Bancroft GJ, Lertmemongkolchai G
Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei
2009
3
4
e407
PLoS neglected tropical diseases
Wiki: B. pseudomallei
website
Wiki: B. pseudomallei
http://en.wikipedia.org/wiki/Burkholderia_pseudomallei
Woo et al., 2001
journal
Woo PC, Leung PK, Wong SS, Ho PL, Yuen KY
groEL encodes a highly antigenic protein in Burkholderia pseudomallei
2001
8
4
832-836
Clinical and diagnostic laboratory immunology